Full Fed. Circ. Won't Let Hospira Escape $70M Epogen IP Loss
The full Federal Circuit on Monday said it won't review a $70 million infringement verdict against Hospira Inc. in a fight over its biosimilar version of Amgen's biologic Epogen....To view the full article, register now.
Already a subscriber? Click here to view full article